Belldegrun Arie
- SEC CIK
- 0001296549
No open-market purchases or sales filed in the past year.
Current role at each company
- URGN UroGen Pharma Ltd.Directoras of Jun 24, 2026
- ALLO Allogene Therapeutics, Inc.Directoras of Feb 4, 2026
- LBRX LB Pharmaceuticals Inc10% Owneras of Sep 16, 2025
- KRON Kronos Bio, Inc.Directoras of Jun 20, 2025
- DNA Ginkgo Bioworks Holdings, Inc.Directoras of Jun 14, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Belldegrun Arie as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
LBRX LB Pharmaceuticals Inc
10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2025 (view filing)3:46 PM ET | Sep 12 | 4 days | Belldegrun Arie and 4 others10% Owner | PPurchase | +333.3K | $15.00 | +$5.00M | New position2.03K after | 2 lots |
ALLO Allogene Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2024 (view filing) | May 16 | 4 days | Belldegrun ArieDirector | PPurchase | +1.72M | $2.90 | +$5.00M | New position1.72M after | |
| Jan 14, 2022 (view filing) | Jan 12 | 2 days | Belldegrun ArieDirector | PPurchase | +155.0K | $12.60 | +$1.95M | +387.6%195.0K after |